194 related articles for article (PubMed ID: 27982762)
1. The response of spinal cord ependymomas to bevacizumab in patients with neurofibromatosis Type 2.
J Neurosurg Spine; 2017 Apr; 26(4):474-482. PubMed ID: 27982762
[TBL] [Abstract][Full Text] [Related]
2. Bevacizumab treatment for symptomatic spinal ependymomas in neurofibromatosis type 2.
Farschtschi S; Merker VL; Wolf D; Schuhmann M; Blakeley J; Plotkin SR; Hagel C; Mautner VF
Acta Neurol Scand; 2016 Jun; 133(6):475-80. PubMed ID: 26369495
[TBL] [Abstract][Full Text] [Related]
3. Bevacizumab as a surgery-sparing agent for spinal ependymoma in patients with neurofibromatosis type II: Systematic review and case.
Snyder MH; Ampie L; DiDomenico JD; Asthagiri AR
J Clin Neurosci; 2021 Apr; 86():79-84. PubMed ID: 33775351
[TBL] [Abstract][Full Text] [Related]
4. Clinical response associated with radiographic regression of a cervicomedullary ependymoma in a NF2 patient treated by bevacizumab.
Essayed WI; Bernard A; Kalamarides M
J Neurooncol; 2015 Nov; 125(2):445-6. PubMed ID: 26337624
[No Abstract] [Full Text] [Related]
5. Spinal ependymomas in neurofibromatosis Type 2: a retrospective analysis of 55 patients.
Plotkin SR; O'Donnell CC; Curry WT; Bove CM; MacCollin M; Nunes FP
J Neurosurg Spine; 2011 Apr; 14(4):543-7. PubMed ID: 21294614
[TBL] [Abstract][Full Text] [Related]
6. Spinal ependymomas in NF2: a surgical disease?
Kalamarides M; Essayed W; Lejeune JP; Aboukais R; Sterkers O; Bernardeschi D; Peyre M; Lloyd SK; Freeman S; Hammerbeck-Ward C; Kellett M; Rutherford SA; Evans DG; Pathmanaban O; King AT
J Neurooncol; 2018 Feb; 136(3):605-611. PubMed ID: 29188529
[TBL] [Abstract][Full Text] [Related]
7. Clinical presentation, immunohistochemistry and electron microscopy indicate neurofibromatosis type 2-associated gliomas to be spinal ependymomas.
Hagel C; Stemmer-Rachamimov AO; Bornemann A; Schuhmann M; Nagel C; Huson S; Evans DG; Plotkin S; Matthies C; Kluwe L; Mautner VF
Neuropathology; 2012 Dec; 32(6):611-6. PubMed ID: 22394059
[TBL] [Abstract][Full Text] [Related]
8. Multicenter, Prospective, Phase II and Biomarker Study of High-Dose Bevacizumab as Induction Therapy in Patients With Neurofibromatosis Type 2 and Progressive Vestibular Schwannoma.
Plotkin SR; Duda DG; Muzikansky A; Allen J; Blakeley J; Rosser T; Campian JL; Clapp DW; Fisher MJ; Tonsgard J; Ullrich N; Thomas C; Cutter G; Korf B; Packer R; Karajannis MA
J Clin Oncol; 2019 Dec; 37(35):3446-3454. PubMed ID: 31626572
[TBL] [Abstract][Full Text] [Related]
9. Sustained response to bevacizumab in a patient with mosaic neurofibromatosis type 2 carrying the
Basenach E; Förster A; Raab P; Alzein S; Schmidt G; Krauss JK; Schlegelberger B; Heidenreich F; Auber B; Hartmann C; Wiese B; Weber RG
Clin Neuropathol; 2022; 41(4):162-167. PubMed ID: 35445657
[TBL] [Abstract][Full Text] [Related]
10. The effect of bevacizumab on vestibular schwannoma tumour size and hearing in patients with neurofibromatosis type 2.
Alanin MC; Klausen C; Caye-Thomasen P; Thomsen C; Fugleholm K; Poulsgaard L; Lassen U; Mau-Sorensen M; Hofland KF
Eur Arch Otorhinolaryngol; 2015 Dec; 272(12):3627-33. PubMed ID: 25421643
[TBL] [Abstract][Full Text] [Related]
11. Bevacizumab decreases vestibular schwannomas growth rate in children and teenagers with neurofibromatosis type 2.
Hochart A; Gaillard V; Baroncini M; André N; Vannier JP; Vinchon M; Dubrulle F; Lejeune JP; Vincent C; Nève V; Sudour Bonnange H; Bonne NX; Leblond P
J Neurooncol; 2015 Sep; 124(2):229-36. PubMed ID: 26022982
[TBL] [Abstract][Full Text] [Related]
12. Molecular genetic analysis of ependymal tumors. NF2 mutations and chromosome 22q loss occur preferentially in intramedullary spinal ependymomas.
Ebert C; von Haken M; Meyer-Puttlitz B; Wiestler OD; Reifenberger G; Pietsch T; von Deimling A
Am J Pathol; 1999 Aug; 155(2):627-32. PubMed ID: 10433955
[TBL] [Abstract][Full Text] [Related]
13. [Neurofibromatosis type 2].
Goutagny S; Bouccara D; Bozorg-Grayeli A; Sterkers O; Kalamarides M
Rev Neurol (Paris); 2007 Sep; 163(8-9):765-77. PubMed ID: 17878803
[TBL] [Abstract][Full Text] [Related]
14. Molecular genetic alterations on chromosomes 11 and 22 in ependymomas.
Lamszus K; Lachenmayer L; Heinemann U; Kluwe L; Finckh U; Höppner W; Stavrou D; Fillbrandt R; Westphal M
Int J Cancer; 2001 Mar; 91(6):803-8. PubMed ID: 11275983
[TBL] [Abstract][Full Text] [Related]
15. Is NF2 a Key Player of the Differentially Expressed Gene Between Spinal Cord Ependymoma and Intracranial Ependymoma?
Kim KT; Lee CH; Chung CK; Kim JH
World Neurosurg; 2018 Oct; 118():e906-e917. PubMed ID: 30031196
[TBL] [Abstract][Full Text] [Related]
16. Bevacizumab for progressive vestibular schwannoma in neurofibromatosis type 2: a retrospective review of 31 patients.
Plotkin SR; Merker VL; Halpin C; Jennings D; McKenna MJ; Harris GJ; Barker FG
Otol Neurotol; 2012 Aug; 33(6):1046-52. PubMed ID: 22805104
[TBL] [Abstract][Full Text] [Related]
17. Cerebral and spinal cord tanycytic ependymomas in a young adult with a mutation in the NF2 gene.
Kuga Y; Ohnishi H; Kodama Y; Takakura S; Hayashi M; Yagi R; Fukutome K; Matsushima K; Okamoto K; Taomoto K; Takahashi H
Neuropathology; 2014 Aug; 34(4):406-13. PubMed ID: 24612193
[TBL] [Abstract][Full Text] [Related]
18. Bevacizumab treatment for vestibular schwannoma in a patient with neurofibromatosis type 2: hearing improvement and tumor shrinkage.
Sponghini AP; Platini F; Rondonotti D; Soffietti R
Tumori; 2015 Nov; 101(6):e167-70. PubMed ID: 26108240
[TBL] [Abstract][Full Text] [Related]
19. Effect of bevacizumab on intracranial meningiomas in patients with neurofibromatosis type 2 - a retrospective case series.
Alanin MC; Klausen C; Caye-Thomasen P; Thomsen C; Fugleholm K; Poulsgaard L; Lassen U; Mau-Sorensen M; Hofland KF
Int J Neurosci; 2016 Nov; 126(11):1002-6. PubMed ID: 26365467
[TBL] [Abstract][Full Text] [Related]
20. MYCN immunohistochemistry as surrogate marker for MYCN-amplified spinal ependymomas.
Mohan D; Nambirajan A; Malik R; Sharma A; Suri V; Kaur K; Doddamani R; Garg A; Gupta S; Mallick S; Sharma MC
Hum Cell; 2024 May; 37(3):704-713. PubMed ID: 38411836
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
